AZ Makes Fresh mRNA Move With Ethris Respiratory Pact

A long-time player in messenger RNA through its partnership with Moderna Therapeutics, AstraZeneca has paid €25m upfront to a German biotech to find targets for investigation in asthma, COPD and idiopathic pulmonary fibrosis.

Attractive senior woman savoring the moment standing with her eyes closed and head tilted back with a serene expression as she clasps her chest with her hands
And Breathe: AstraZeneca has boosted its early-stage respiratory pipeline • Source: Shutterstock

AstraZeneca PLC is expanding its presence in the messenger RNA space through a collaboration with German biotech Ethris GMBH that will focus on its core respiratory area.

The five-year deal will see the companies develop new stabilized non-immunogenic modified (SNIM) RNA therapies for respiratory diseases using Ethris’...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.